Citation Impact
Citing Papers
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
2008 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Thiazolidinediones
2004 Standout
Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus
2001
The Many Faces of PPARγ
2005
ω-6 Polyunsaturated fatty acids extend life span through the activation of autophagy
2013 StandoutNobel
Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial
2006
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
2006
Infliximab for acute, not steroid-refractory ulcerative colitis
2004
A Multicenter, Randomized, Double-Blind Trial of EverolimusVersusAzathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease
2008
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
Inflammation and metabolic disorders
2006 StandoutNature
Myasthenia Gravis
2016 Standout
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
2015
Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
2010
Rheumatoid arthritis
2016 Standout
Intestinal homeostasis and its breakdown in inflammatory bowel disease
2011 StandoutNature
NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis
2011 Standout
Importance of mucosal healing in ulcerative colitis
2009
Ulcerative Colitis
2011 Standout
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
2005
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium
2007 StandoutNobel
Unravelling the pathogenesis of inflammatory bowel disease
2007 StandoutNature
The Failing Heart — An Engine Out of Fuel
2007 Standout
Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
2000
Peroxisome Proliferator-Activated Receptor Gamma Agonist Ligands Stimulate a Th2 Cytokine Response and Prevent Acute Colitis
2002
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
2005
Nonalcoholic Fatty Liver Disease
2002 Standout
Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease
2012
Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA
2003
Infliximab for patients with refractory ulcerative colitis
2001
A Pilot Study of A Thiazolidinedione, Troglitazone, in Nonalcoholic Steatohepatitis
2001
Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
2009
Clostridium difficile and inflammatory bowel disease
2008
Inflammatory Bowel Disease
2009 Standout
Acute Pancreatitis
2016 Standout
Human nutrition, the gut microbiome and the immune system
2011 StandoutNature
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Metagenomic biomarker discovery and explanation
2011 Standout
Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis
2002
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Skeletal remodeling in health and disease
2007 Standout
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Intestinal‐specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice
2006
Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice
2000
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008
Future biologic targets for IBD: potentials and pitfalls
2010
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
2008
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Graves' Ophthalmopathy
2010 Standout
Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis
2003
Inflammatory Bowel Disease
2002 Standout
Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
2013
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
2007
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
The Impact of the Gut Microbiota on Human Health: An Integrative View
2012 Standout
A Unique PPARγ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity
2001
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
2009
Certolizumab Pegol for the Treatment of Crohn's Disease
2007
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort
2015
Medical therapy for ulcerative colitis 2004
2004
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
2012
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
2006
Ulcerative colitis
2016 Standout
Combinatorial roles of nuclear receptors in inflammation and immunity
2005
Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study
2007 Standout
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Evolving knowledge and therapy of inflammatory bowel disease
2006
What We Talk About When We Talk About Fat
2014 Standout
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial
2003
A microbial symbiosis factor prevents intestinal inflammatory disease
2008 StandoutNature
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Anti–Interleukin-12 Antibody for Active Crohn's Disease
2004
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
2015
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
2007
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Atherosclerosis
2001 Standout
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
2014 Standout
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Medical therapy for ulcerative colitis
2000
A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease
2006
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
2006
Management of Crohn's Disease in Adults
2009 Standout
Colectomy rate in acute severe ulcerative colitis in the infliximab era
2008
Helicobacter pylori and gastrointestinal tract adenocarcinomas
2002
War and peace at mucosal surfaces
2004
Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
2008
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
2017
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
2006
The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity
2009
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ
2005
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
2000
Hypoxia-Inducible Factor 1-Mediated Inhibition of Peroxisome Proliferator-Activated Receptor α Expression During Hypoxia
2001
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015
The Mechanisms of Action of PPARs
2002 Standout
Peroxisome Proliferator-Activated Receptor-γ-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis
2003
Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine
2010
Pioglitazone, a Peroxisome Proliferator–Activated Receptor-γ Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction
2002
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
Heterozygous α 2A -adrenergic receptor mice unveil unique therapeutic benefits of partial agonists
2002 StandoutNobel
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
2007
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
2008
Inflammatory Bowel Disease
2010 Standout
Future perspectives in target-specific immunotherapies of myasthenia gravis
2015
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Systemic Analysis of PPARγ in Mouse Macrophage Populations Reveals Marked Diversity in Expression with Critical Roles in Resolution of Inflammation and Airway Immunity
2012
PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages
2003
Host-Gut Microbiota Metabolic Interactions
2012 StandoutScience
Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response
2009 StandoutNobel
European evidence-based Consensus on the management of ulcerative colitis: Current management
2008
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
2008
NUCLEAR RECEPTORS IN MACROPHAGE BIOLOGY: At the Crossroads of Lipid Metabolism and Inflammation
2004
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands
2010 StandoutNobel
Emerging roles of PPARS in inflammation and immunity
2002
Works of Chinyu Su being referenced
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
2002
The Effect of Anti‐TNF‐α Therapy on Spinal Bone Mineral Density in Patients with Crohn's Disease
2006
Extraintestinal manifestations of inflammatory bowel disease
2002
A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis
2006
Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
2000
An open-label trial of the PPARgamma ligand rosiglitazone for active ulcerative colitis
2001
Are there predictors of Remicade treatment success or failure?
2004
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
2004
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2012
A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease
2004
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
1999
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
2015
Trends in Hospitalization Rates for Inflammatory Bowel Disease in the United States
2007
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017
Antineoplastic and anti–inflammatory effects of PPAR ligands in colitis
2001
Tu1109 Evaluation of the Relationship Between Fecal Calprotectin Concentrations and Clinical and Endoscopic Outcome Measures in a Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2013